MedTrace Logo

Ultra Curto (Ultra Short) TB Prevention Therapy

NCT04703075 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 531

Last updated 2025-06-19

Study results available
· View outcomes & findings →

Summary

To compare treatment success (adherence and completion of treatment) and safety of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB.

Conditions

Interventions

DRUG

Rifapentine 600 mg and INH 300 mg

Participants will receive Rifapentine 600 mg and INH 300 mg

DRUG

Rifapentine 900 mg and INH 900 mg

Participants will receive Rifapentine 900 mg and INH 900mg

Sponsors & Collaborators

Principal Investigators

  • Richard Chaisson, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2024-06-10
Completion
2024-06-10

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703075 on ClinicalTrials.gov